P/E ratio for Adial Pharmaceuticals (ADIL)
P/E ratio as of July 2025 (TTM): -0.1800
According to Adial Pharmaceuticals 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.18. At the end of 2024 the company had a P/E ratio of -0.3787.
P/E ratio history for Adial Pharmaceuticals from 2018 to 2025
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2024 | -0.3787 | -26.71% |
| 2023 | -0.5167 | 19.4% |
| 2022 | -0.4327 | -83.14% |
| 2021 | -2.57 | 24.78% |
| 2020 | -2.06 | -32.2% |
| 2019 | -3.03 | 13.91% |
| 2018 | -2.66 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 NRC Health
NRC | 13.5 | -7,616.17% | 🇺🇸 USA |
 Nymox Pharmaceutical NYMX | -3.33 | 1,751.85% | Bahamas |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.